Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Ranibizumab for Nonproliferative Idiopathic Parafoveal Telangiectasia
NCT01205035Phase 2Completed
- Sponsor
- Eye Center of Northern Colorado
- Start
- Oct 2010
- Primary completion
- Oct 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in macular telangiectasia (MacTel), sponsored by Eye Center of Northern Colorado. Started Oct 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular telangiectasia (MacTel)
Beyond the preview
Go deeper on NCT01205035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01205035.